Eagle pharmaceuticals, inc. (EGRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent

-2,871

1,005

-2,390

6,725

8,973

12,590

14,038

2,659

2,616

9,085

15,431

4,503

22,924

57,301

11,950

13,098

-896

1,219

-10,168

-8,177

19,697

-5,506

-9,103

-2,935

-2,684

-3,255

Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income taxes

-90

327

-48

160

-287

-4,508

503

1,660

-123

5,148

3,773

4,156

4,212

-30,116

0

0

0

-

-

-

-

0

-

-

-

-

Depreciation expense

472

652

474

502

503

237

235

342

341

275

225

236

196

180

165

156

140

81

9

10

12

13

22

22

29

31

Amortization expense

666

630

630

630

630

599

600

646

670

680

712

711

712

487

201

156

104

0

0

0

0

0

-

-

-

-

Fair value adjustments on equity investment

-6,500

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

7,472

5,183

5,651

5,382

5,782

4,570

4,472

4,735

5,305

3,811

3,728

3,697

4,193

2,229

2,250

2,420

2,869

1,109

1,349

1,209

384

284

224

164

140

78

Change in fair value of contingent consideration

-

-

-

-

-

0

0

-790

27

-1,773

-6,452

422

426

330

232

236

159

0

0

0

0

0

-

-

-

-

Amortization of debt issuance costs

65

198

94

94

94

94

94

94

94

94

62

66

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

27

-

-

0

0

-

-

-

-

-

-

-

-

-

Gain (Loss) on Disposition of Assets

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,750

0

0

0

0

0

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

383

191

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-273

0

0

0

0

-

Changes in operating assets and liabilities which provided (used) cash:
Accounts receivable

6,487

3,193

-15,527

-3,591

-2,556

-11,975

9,058

15,977

-395

-17,780

18,371

-31,512

42,548

-4,864

-4,977

25,501

259

14,049

-764

2,474

-1,448

4,660

584

-1,108

1,228

1,468

Inventories

1,868

-682

-4,347

1,329

1,961

1,031

1,098

2,404

1,023

240

1,291

572

276

-4,367

743

-1,398

-7,281

7,694

5,023

307

776

-52

965

329

0

0

Prepaid expenses and other current assets

-4,473

4,588

4,918

-297

-4,368

-10,547

-4,996

12,223

-1,518

1,234

-3,534

3,559

-3,252

5,717

4,032

-502

183

-2,794

3,198

219

-300

-71

788

90

464

-1,534

Other assets

-

-

-

-

-

-

-

-

-

12

-38

-1

27

49

0

0

-49

-

7

59

0

0

1

0

-1

-

Accounts payable

4,294

-5,770

-6,064

510

6,869

2,373

-10,722

8,913

-2,628

-2,646

-3,246

-6,879

4,311

2,921

173

1,136

6,438

-10,291

9,365

-602

1,884

-558

1,539

62

112

1,154

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-6,000

0

-260

-325

65

-65

325

-3,435

-325

0

Accrued expenses and other liabilities

-8,238

459

-1,272

5,963

-1,083

652

-355

10,120

-2,289

-5,047

2,508

3,281

-9,838

2,758

-2,005

3,775

-4,844

9,966

534

-1,176

2,549

2,494

2,203

766

1,965

1,758

Other assets and other long-term liabilities, net

1,230

-

1,417

133

263

-

0

600

-18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

3,158

-3,201

10,614

22,392

26,181

38,108

3,688

5,667

4,921

25,921

7,886

37,548

-12,436

39,555

13,168

-2,624

3,108

-16,799

-6,635

-12,120

25,836

-7,875

-7,128

-4,667

-2,071

23

Cash flows from investing activities:
Purchase of equity investment security

17,500

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

472

130

304

166

177

81

33

0

19

2,730

822

208

676

507

179

100

804

483

1,071

284

43

11

7

4

28

7

Purchase of short term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

62,000

0

16,000

74,001

15,998

0

19,999

0

0

-

Maturities of short term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

62,000

24,000

81,999

0

0

19,999

0

0

0

0

Payments to Acquire Businesses, Gross

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,850

0

0

0

0

0

-

-

-

-

Payment for Ryanodex intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Purchase of Eagle Biologics, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from sale of diclofenac-misoprostol

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,750

0

0

0

0

0

-

-

-

-

Net cash used in investing activities

-17,972

-130

-304

-166

-177

-81

-33

0

-19

-2,730

-1,572

-208

-676

-27,617

-14,179

-100

-3,904

23,517

64,928

-74,285

-16,041

19,988

-20,006

-4

-28

-7

Cash flows from financing activities:
Payments for employee net option exercises

-

-

-

-

-

0

0

1,826

3,051

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred IPO costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1

-498

Series C preferred stock offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from exercise of preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

21

-

Proceeds from issuance of common stock from initial public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from issuance of common stock from follow-on public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-365

54,696

0

-

-

-

-

Proceeds from common stock option exercises

330

182

23

13

42

14

1,933

5,502

1,166

173

35

1,993

2,137

2,133

1,486

0

0

386

0

532

564

34

65

0

0

0

Payment of debt financing costs

-

-

-

-

-

-

-

-

-

0

710

0

482

0

0

0

0

-

-

-

-

-

-

-

-

-

Employee withholding taxes related to stock-based awards

1,276

0

0

0

198

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

-1

0

0

15,001

0

0

0

0

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from long-term debt

110,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt

1,000

1,000

1,250

1,250

2,500

0

2,500

1,250

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of common stock

999

2,961

0

15,000

0

50,477

12,109

3,516

7,003

5,002

13,479

11,658

13,653

20,506

16,497

0

0

-

-

-

-

0

-

-

-

-

Net cash provided by (used in) financing activities

107,055

-4,105

-1,227

-16,237

-2,656

-50,462

-12,676

-1,090

-23,889

-6,079

35,846

-9,665

-11,998

-18,429

-15,241

0

0

386

0

167

55,260

34

65

-418

47,005

-498

Net increase in cash and cash equivalents

92,241

-7,436

9,083

5,989

23,348

-12,435

-9,021

4,577

-18,987

17,112

42,160

27,675

-25,110

-6,491

-16,252

-2,724

-796

7,104

58,293

-86,238

65,055

12,147

-27,069

-5,089

44,906

-482

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest

576

691

566

596

625

544

1,011

161

368

651

0

0

0

-

-

-

-

-

-

3

1

1

2

5

1

0

Right-of-use asset obtained in exchange for lease obligation - lease amendment

842

-

-

-

2,871

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-5,158

5,158

-

Income taxes, net

24

86

3,713

9,364

-6,490

394

56

1,735

96

1,697

3,260

5,585

0

-

-

-

-

0

295

187

0

0

-

-

-

-

Non-cash operating activities
Landlord contribution to leasehold improvements recorded as deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Contingent consideration - business acquisitions

-

-

-

-

-

-

-

-

-

-

-

-

-

16,100

0

0

6,370

0

0

0

0

0

-

-

-

-

Conversion of note payable to Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-547

414

133

Franchise taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

53

-

0

0

8

1

Accrued follow-on public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-365

365

-

-

-

0

-